ProQR Therapeutics (PRQR) Short term Debt (2017 - 2026)

ProQR Therapeutics (PRQR) has reported Short term Debt for 10 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• Quarterly Short term Debt rose 6.23% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 6.23% YoY) and the FY2025 annual result came in at $5.5 million, up 6.33% from the prior year.
• Short term Debt climbed to $5.6 million in Q1 2026 per PRQR's latest filing, from $5.5 million in the prior quarter.
• Over the last five years, Short term Debt for PRQR reached as high as $8.2 million in Q2 2022 and fell as low as $2.1 million in Q3 2022.
• A 5-year average of $4.8 million and a median of $5.2 million in 2024 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2022 — Short term Debt surged 361.84% — and 2023, when it slumped 59.71%.
• Year by year, Short term Debt stood at $2.8 million in 2022, then dropped by 6.24% to $2.7 million in 2023, then soared by 95.48% to $5.2 million in 2024, then advanced by 6.33% to $5.5 million in 2025, then gained by 1.5% to $5.6 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.6 million, $5.5 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.